Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Relay Therapeutics Inc (NQ: RLAY )

4.860 +0.110 (+2.32%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Relay Therapeutics Inc

< Previous 1 2 3 4 5 6 Next >
AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual... 
Via Talk Markets
Why Relay Therapeutics Plummeted by Nearly 14% Today
Investors weren't happy with the company's latest effort at capital-raising. 
Via The Motley Fool
Why Relay Therapeutics (RLAY) Stock Is Down 17% Today
Relay Therapeutics shares are trading lower by 17.8% during Wednesday's session. The company priced its $200 million offering. 
Via Benzinga
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
Via Benzinga
GameStop Reports Weak Sales, Joins Petco, Relay Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Expert Ratings For Relay Therapeutics
Via Benzinga
Expert Ratings For Relay Therapeutics
Via Benzinga
Expert Ratings For Relay Therapeutics
Via Benzinga
Why Dave & Buster's Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Relay Therapeutics Faces Downgrade Over Efficacy Concerns in Competitive PI3K Inhibitor Market
Relay Therapeutics shares interim data for RLY-2608 from the ReDiscover study, showing a 57% clinical benefit rate. Oppenheimer downgrades Relay Therapeutics from Outperform to Perform, citing concerns... 
Via Benzinga
AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual... 
Via Talk Markets
This Johnson Controls International Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
Dow Jumps Over 1% Following Last Week's Selloff: Investor Sentiment Improves, But Fear & Greed Index Remains In 'Fear' Zone
Via Benzinga
Topics Stocks
Exposures US Equities
Crude Oil Gains Over 1%; Relay Therapeutics Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
Nasdaq Surges Over 1%; US Wholesale Inventories Rise 0.2% In July
Via Benzinga
Relay Therapeutics Advances Towards Pivotal Trial As It Shares Encouraging Breast Cancer Data In Heavily Pretreated Patients
Monday, Relay Therapeutics Inc. (NASDAQ:RLAY) shared interim data for RLY-2608 from ReDiscover study, an ongoing first-in-human study, to evaluate the safety, tolerability, pharmacokinetics,... 
Via Benzinga
Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday
Via Benzinga
US Stocks Higher; Dow Surges Over 200 Points
Via Benzinga
Topics Stocks
Exposures US Equities
Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!
The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug... 
Via Talk Markets
Topics Economy
Exposures Economy
Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030. 
Via Talk Markets
RLAY Stock Earnings: Relay Therapeutics Beats EPS for Q2 2024
RLAY stock results show that Relay Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD
The AI-powered drug discovery process is expected to grow by a CAGR of 30% by 2030. 
Via Talk Markets
These 7 AI Stocks Were Major Movers On Monday/Tuesday - Here's Why
This article identifies the 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD
To capitalize on the transition to more AI-focused drug development investors need to understand the drug development process and the financial health and market potential of those companies under... 
Via Talk Markets
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,... 
Via Talk Markets
Clinical-Stage BioTech Drug Stocks Declined 13% In June
Our BioTech Drug Stocks Portfolio was DOWN 13.2% in June. Before proceeding read 
Via Talk Markets
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they... 
Via Talk Markets
AI-Focused Drug Discovery Stocks Portfolio Down 4% W/e June 14th
The global 
Via Talk Markets
AI-Focused Drug Discovery Stocks Portfolio Down 2% In May; Up 4% Last Week
The global 
Via Talk Markets
Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week
This article highlights the performances last week and MTD of the 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies along with their areas of focus in our... 
Via Talk Markets
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.